« PreviousContinue »
notified by FDA that its exemption approval has been terminated, file a supplemental application for the new use that is the subject of the information being disseminated under the exemption, certify, under 899.201(a)(4)(i) or (a)(4)(ii) that it will file a supplemental application for the new use, or cease disseminating the information on the new use. FDA may require a manufacturer that ceases dissemination of information on the new use to undertake corrective action.
8 99.405 Applicability of labeling, adul.
teration, and misbranding author
ity. The dissemination of information relating to a new use for a drug or device may constitute labeling, evidence of a new intended use, adulteration, or misbranding of the drug or device if such dissemination fails to comply with section 551 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360aaa) and the requirements of this part. A manufacturer's failure to exercise due diligence in submitting the clinical studies that are necessary for the approval of a new use that is the subject of information disseminated under this part or in beginning or completing such clinical studies shall be deemed a failure to comply with section 551 of the act and the requirements of this part.
identify recipients by category only shall:
(A) Identify subcategories of recipients where appropriate (e.g., oncologists, pediatricians, obstetricians, etc.); and
(B) Ensure that any corrective action to be taken will be sufficiently conspicuous to individuals within that category of recipients;
(2) Maintain an identical copy of the information disseminated under this part; and
(3) Upon the submission of a supplemental application to FDA, notify the appropriate office identified in 899.201(c) of this part.
(b) A manufacturer disseminating information on a new use for a drug or device shall, on a semiannual basis, submit to the FDA office identified in 899.201(c) of this part:
(1) A list containing the titles of articles and reference publications relating to the new use of drugs or devices that the manufacturer disseminated to a health care practitioner, pharmacy benefit manager, health insurance issuer, group health plan, or Federal or State Government agency. The list shall cover articles and reference publications disseminated in the 6-month period preceding the date on which the manufacturer provides the list to FDA;
(2) A list identifying the categories of health care practitioners, pharmacy benefit managers, health insurance issuers, group health plans, or Federal or State Government agencies that received the articles and reference publications in the 6-month period described in paragraph (b)(1) of this section. The list shall also identify which category of recipients received a particular article or reference publication;
(3) A notice and summary of any additional clinical research or other data relating to the safety or effectiveness of the new use, and, if the manufacturer possesses such clinical research or other data, a copy of the research or data. Such other data may include, but is not limited to, new articles published in scientific or medical journals, reference publications, and summaries of adverse effects that are or may be associated with the new use;
(4) If the manufacturer is conducting studies necessary for the submission of
Subpart F-Recordkeeping and
Reports $ 99.501 Recordkeeping and reports.
(a) A manufacturer disseminating information under this part shall:
(1) Maintain records sufficient to allow the manufacturer to take corrective action as required by FDA. The manufacturer shall make such records available to FDA, upon request, for inspection and copying. Such records shall either:
(i) Identify, by name, those persons receiving the disseminated information; or
(ii) Identify, by category, the recipients of the disseminated information, unless FDA requires the manufacturer to retain records identifying individual recipients of the disseminated information. Manufacturers whose records
a supplemental application, the manufacturer shall submit periodic progress reports on these studies to FDA. Such reports shall describe the studies' current status (i.e., progress on patient enrollment, any significant problems that could affect the manufacturer's ability to complete the studies, and expected completion dates). If the manufacturer discontinues or terminates a study before completing it, the manufacturer shall, as part of the next periodic progress report, state the reasons for such discontinuation or termination; and
(5) If the manufacturer was granted an exemption from the requirements to submit a supplemental application for the new use, any new or additional information that relates to whether the manufacturer continues to meet the re
quirements for such exemption. This information may include, but is not limited to, new or additional information regarding revenues from the product that is the subject of the dissemination and new or additional information regarding the persuasiveness of the data on the new use, including information regarding whether the new use is broadly accepted as current standard medical treatment or therapy.
(c) A manufacturer shall maintain a copy of all information, lists, records, and reports required or disseminated under this part for 3 years after it has ceased dissemination of such information and make such documents available to FDA for inspection and copying.
A list of CFR titles, subtitles, chapters, subchapters and parts and an alphabetical list of agencies publishing in the CFR are included in the CFR Index and Finding Aids volume to the Code of Federal Regulations which is published separately and revised annually.
Material Approved for Incorporation by Reference
Material Approved for Incorporation by Reference
(Revised as of April 1, 2002)
The Director of the Federal Register has approved under 5 U.S.C. 552(a) and 1 CFR Part 51 the incorporation by reference of the following publications. This list contains only those incorporations by reference effective as of the revision date of this volume. Incorporations by reference found within a regulation are effective upon the effective date of that regulation. For more information on incorporation by reference, see the preliminary pages of this volume.
21 CFR (PARTS 1 TO 99)
21 CFR AOAC International (Association of Official Analytical Chemists)
481 N. Frederick Ave., Suite 500, Gaithersburg, MD 20877-2407
Telephone: (301) 924-7077
2.19 Note: The following materials are available through the Food and
Drug Administration at the addresses indicated.
200 C St. SW., Washington DC 20204 Measure Container Code of the National Bureau of Standards Hand- 1.24(a)(6)(i), (ii) and
book 44 "Sec. 4.45 Measure-Containers”. International Organization for Standardization
1 rue de Varembe, Case postale 56, CH-1211 Geneve 20, Switzer
land Guide 2: Standardization and Related Activities - General Vocabulary 26.60(b)
of the International Organization for Standardization (ISO) and
the International Electrotechnical Commission (IEC), 1998 Edition. National Academy Press
2101 Constitution Ave., NW., Box 285, Washington, DC 20055 Food Chemicals Codex, 3d Ed (1981)
73.160 (a) and (b);
73.450 (a) and (b) Food Chemicals Codex, 4th Ed (1996) ..........